Skip to content
HowShorted

Prestige Consumer Healthcare Inc. short interest in 2022

In 2022, Prestige Consumer Healthcare Inc.'s disclosed short interest ran from 2.47% of shares outstanding on 14 Jan 2022 to 2.21% on 30 Dec 2022, a change of -0.26 percentage points. The year's high was 2.76% on 30 Sep 2022 and its low 1.74% on 15 Feb 2022, averaging 2.27% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.16 days on 14 Jan 2022. Full history: Prestige Consumer Healthcare Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Prestige Consumer Healthcare Inc. in 2022

2022 in figures

Start of year
2.47% (14 Jan 2022)
End of year
2.21% (30 Dec 2022)
Change
-0.26 pp
High
2.76% (30 Sep 2022)
Low
1.74% (15 Feb 2022)
Average
2.27%
Highest days to cover
7.16 (14 Jan 2022)
SEC filings marked
8

Every report in 2022

Prestige Consumer Healthcare Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20222.47%7.16
31 Jan 20222.23%3.63
15 Feb 20221.74%2.3410-Q filed, results (8-K)
28 Feb 20221.77%3.79
15 Mar 20221.91%3.27
31 Mar 20221.99%3.51
14 Apr 20221.89%4.06
29 Apr 20221.88%4.02
13 May 20222.02%2.99results (8-K), 10-K filed
31 May 20221.99%3.93
15 Jun 20222.31%5.42
30 Jun 20222.46%3.28
15 Jul 20222.67%5.46
29 Jul 20222.60%5.52
15 Aug 20222.44%3.8910-Q filed, results (8-K)
31 Aug 20222.52%5.56
15 Sep 20222.64%4.80
30 Sep 20222.76%3.94
14 Oct 20222.76%6.04
31 Oct 20222.71%6.23
15 Nov 20222.21%5.0110-Q filed, results (8-K)
30 Nov 20222.27%4.77
15 Dec 20222.04%3.76
30 Dec 20222.21%4.00

See also: Prestige Consumer Healthcare Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.